Protagonist Therapeutics Inc (NASDAQ:PTGX) has been assigned a consensus rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $17.33.
Several research firms have recently commented on PTGX. Leerink Swann increased their price objective on Protagonist Therapeutics from $13.00 to $21.00 and gave the company an “outperform” rating in a report on Monday, August 6th. ValuEngine raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 18th. Finally, Zacks Investment Research raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 11th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC raised its stake in Protagonist Therapeutics by 255.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock valued at $100,000 after acquiring an additional 8,327 shares during the period. Prudential Financial Inc. bought a new stake in Protagonist Therapeutics in the 1st quarter valued at $116,000. Bank of America Corp DE raised its stake in Protagonist Therapeutics by 2,262.7% in the 2nd quarter. Bank of America Corp DE now owns 21,217 shares of the company’s stock valued at $143,000 after acquiring an additional 20,319 shares during the period. Element Capital Management LLC bought a new stake in Protagonist Therapeutics in the 1st quarter valued at $175,000. Finally, LMR Partners LLP bought a new stake in Protagonist Therapeutics in the 2nd quarter valued at $210,000. 57.93% of the stock is owned by institutional investors.
Shares of NASDAQ PTGX traded down $0.22 during trading hours on Friday, hitting $8.77. The company had a trading volume of 39,230 shares, compared to its average volume of 237,147. The company has a market cap of $247.84 million, a PE ratio of -4.20 and a beta of 3.68. Protagonist Therapeutics has a 1-year low of $5.50 and a 1-year high of $23.97.
Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). The company had revenue of $11.67 million during the quarter, compared to analyst estimates of $8.55 million. Protagonist Therapeutics had a negative net margin of 56.92% and a negative return on equity of 24.16%. As a group, equities analysts predict that Protagonist Therapeutics will post -1 EPS for the current fiscal year.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Recommended Story: Find a Trading Strategy That Works
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.